Evolve BioSystems is a privately-held microbiotics company dedicated to developing and bringing to market the next generation of products to establish, restore, and maintain a healthy human microbiome across a range of unmet clinical needs. Evolve is a spin-out from the Foods For Health Institute (FFHI) at the University of California at Davis and builds on more than a decade of research into understanding the uniqueness of the infant microbiome and its intimate interaction with breast milk components. Having led to the discovery and development of products to restore the human infant microbiome to its natural state, Evolve's discovery platform is now being applied to solving dysbiosis issues throughout the human life cycle as well as in similar problems in production animal species. Evolve completed a seed funding round in 2014 and is undertaking multiple clinical trials to confirm the value of its proprietary prebiotic and probiotic assets in returning an infant's microbiome to its naturally evolved state.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/18/15 | $9,000,000 | Series A |
Horizons Ventures Tate & Lyle Ventures | undisclosed |
| 05/30/17 | $20,000,000 | Series B |
Acre Venture Partners Bow Capital Horizons Ventures Spruce Capital Partners  Tate & Lyle Ventures | undisclosed |
| 06/14/18 | $40,000,000 | Series C |
Acre Venture Partners Alta Ventures Arla Foods Bill & Melinda Gates Foundation Bow Capital Continental Grain Horizons Ventures Johnson & Johnson Innovation MLS Capital Tate & Lyle Ventures | undisclosed |
| 02/09/21 | $55,000,000 | Series D |
Cargill Manna Tree Partners | undisclosed |
